Association Between Hepatitis C Virus Infection and Coronary Artery Disease: A Systematic Review and Meta-Analysis
- 1Department of Internal Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Email:
Abstract
Background: Hepatitis C virus (HCV) infection has been associated with cardiovascular disease, but its relationship with coronary artery disease (CAD) remains uncertain.
Methods: This systematic review included observational studies reporting adjusted effect estimates for CAD outcomes among HCV-infected and HCV-uninfected adults. Adjusted hazard ratios, risk ratios, and odds ratios were combined on the logarithmic scale using a random-effects model and are presented as a summary relative association estimate with 95% confidence intervals (CIs). Prespecified subgroup analyses were performed by study design, human immunodeficiency virus (HIV) co-infection status, and CAD outcome type; meta-regression evaluated follow-up duration, mean age, and the proportion of male participants.
Results: Twenty-one studies were included, representing diverse populations including veterans, people living with HIV, dialysis patients, and community-based cohorts. Fifteen studies contributed adjusted estimates to the quantitative synthesis. HCV infection was associated with a modest increase in the pooled relative estimate for CAD (summary estimate 1.21; 95% CI, 1.05–1.40; P = 0.007), with substantial heterogeneity (I2 = 72.1%). The association was statistically significant in cohort studies and in both HIV-specific and non-HIV-specific subgroups, although the HIV-specific subgroup was based on four studies. The myocardial infarction (MI)-specific subgroup was not statistically significant, whereas studies using broader CAD outcomes showed a significant association.
Conclusions: Chronic HCV infection was associated with a modest increase in the pooled relative estimate for CAD. However, substantial heterogeneity, differences in endpoint definitions and populations, residual confounding, and the combination of different effect measures limit causal interpretation and make the clinical importance uncertain. The nonsignificant MI-specific analysis further supports a cautious interpretation. These findings do not establish a cardiovascular benefit of antiviral therapy; prospective studies with standardized CAD endpoints and detailed data on renal disease, antiviral exposure, and lipid-lowering therapy are needed.
Related
- Association of adverse pregnancy outcomes with coronary microvascular dysfunction: a systematic review and meta-analysis
- Risk factors for postpartum alanine aminotransferase elevation in women with chronic hepatitis B infection: a systematic review and meta-analysis
- Association between DII and all-cause mortality among older adults with coronary heart disease : A cohort study
- Association between LDL-cholesterol, statin therapy, physical activity and inflammatory markers in patients with stable coronary heart disease
- Association of exercise blood pressure relative to fitness with coronary artery disease.
BibTeX
@article{alhashli2026association,
title = {{Association Between Hepatitis C Virus Infection and Coronary Artery Disease: A Systematic Review and Meta-Analysis}},
author = {Ali Alhashli},
journal = {Cardiology research},
year = {2026},
month = oct,
doi = {10.14740/cr2280},
url = {https://europepmc.org/article/PMC/PMC13719658},
note = {CC BY},
}
RIS
TY - JOUR
TI - Association Between Hepatitis C Virus Infection and Coronary Artery Disease: A Systematic Review and Meta-Analysis
AU - Ali Alhashli
PY - 2026
DA - 2026/10/24
JO - Cardiology research
DO - 10.14740/cr2280
UR - https://europepmc.org/article/PMC/PMC13719658
AB - Background: Hepatitis C virus (HCV) infection has been associated with cardiovascular disease, but its relationship with coronary artery disease (CAD) remains uncertain. Methods: This systematic review included observational studies reporting adjusted effect estimates for CAD outcomes among HCV-infected and HCV-uninfected adults. Adjusted hazard ratios, risk ratios, and odds ratios were combined on the logarithmic scale using a random-effects model and are presented as a summary relative association estimate with 95% confidence intervals (CIs). Prespecified subgroup analyses were performed by study design, human immunodeficiency virus (HIV) co-infection status, and CAD outcome type; meta-regression evaluated follow-up duration, mean age, and the proportion of male participants. Results: Twenty-one studies were included, representing diverse populations including veterans, people living with HIV, dialysis patients, and community-based cohorts. Fifteen studies contributed adjusted estimates to the quantitative synthesis. HCV infection was associated with a modest increase in the pooled relative estimate for CAD (summary estimate 1.21; 95% CI, 1.05–1.40; P = 0.007), with substantial heterogeneity (I2 = 72.1%). The association was statistically significant in cohort studies and in both HIV-specific and non-HIV-specific subgroups, although the HIV-specific subgroup was based on four studies. The myocardial infarction (MI)-specific subgroup was not statistically significant, whereas studies using broader CAD outcomes showed a significant association. Conclusions: Chronic HCV infection was associated with a modest increase in the pooled relative estimate for CAD. However, substantial heterogeneity, differences in endpoint definitions and populations, residual confounding, and the combination of different effect measures limit causal interpretation and make the clinical importance uncertain. The nonsignificant MI-specific analysis further supports a cautious interpretation. These findings do not establish a cardiovascular benefit of antiviral therapy; prospective studies with standardized CAD endpoints and detailed data on renal disease, antiviral exposure, and lipid-lowering therapy are needed.
SN - 1923-2829
SN - 1923-2837
ER -